Drugs / XNW28012
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07707674 | Jul 2026 → Apr 2028 expected | malignant pancreatic neoplasm | Evopoint Biosciences Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06799637 | Dec 2023 → Dec 2026 expected | cervical cancer, exocrine pancreatic carcinoma, ovarian cancer | Evopoint Biosciences Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XNW28012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07707674 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody (mAb)” NCT07707674 ↗ |
| Route | Intravenous | “XNW28012 2.0 mg/kg, IV, every 3 weeks (Q3W; 21-day cycles).” NCT07707674 ↗ |